Immune-related adverse events induced by programmed death protein-1 inhibitors from the perspective of lymphoma immunotherapy

作     者：Yong-Zhe Hou Qin Zhang Hai Bai Tao Wu Ya-Jie Chen 

作者机构：Department of HematologyCenter of Hematologic Diseases of Chinese PLAThe 940th Hospital of Joint Logistics Support force of Chinese People's Liberation ArmyLanzhou 730050Gansu ProvinceChina Department of First Clinical Medical CollegeGansu University of Chinese MedicineLanzhou 730030Gansu ProvinceChina Key Laboratory of Stem Cells and Gene Drugs of Gansu ProvinceLanzhou 730050Gansu ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2023年第11卷第7期

页      面：1458-1466页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the 2022 Project of Innovation Foundation of Outstanding Graduate Students of Gansu Province the Graduate Innovation Foundation of Major Project of Education Department of Gansu Province,No.lccx2021001 the Gansu Provincial Science and Technology Plan Project Assignment(Innovation Base and Talent Plan),No.21JR7RA013 the Gansu Province Innovation Base and Talent Plan(Gansu Province Leukemia Clinical Research Center),No.21JR7RA015 the 2022 Hospital Project of The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army,No.2022yxky015 

主　　题：Lymphoma Programmed cell death 1 receptor Immune checkpoint inhibitors Immune-related adverse events Nivolumab Pembrolizumab 

摘      要：Lymphoma,which is highly malignant,stems from lymph nodes and lymphoid *** cells express programmed death-ligand 1/2(PD-L1/PD-L2),which binds with programmed cell death 1 protein(PD-1)to establish inhibitory signaling that impedes the normal function of T cells and allows tumor cells to escape immune system ***,immune checkpoint inhibitor immunotherapies such as PD-1 inhibitors(nivolumab and pembrolizumab)have been introduced into the lymphoma treatment algorithm and have shown remarkable clinical efficacy and greatly improve prognosis in lymphoma ***,the number of lymphoma patients who are seeking treatment with PD-1 inhibitors is growing annually,which results in an increasing number of patients developing immune-related adverse events(irAEs).The occurrence of irAEs inevitably affects the benefits provided by immunotherapy,particularly when PD-1 inhibitors are ***,the mechanisms and characteristics of irAEs induced by PD-1 inhibitors in lymphoma need further *** review article summarizes the latest research advances in irAEs during treatment of lymphoma with PD-1 inhibitors.A comprehensive understanding of irAEs incurred in immunotherapy can help to achieve better efficacy with PD-1 inhibitors in lymphoma.